相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Population Pharmacokinetics and Hemorrhagic Risk Analysis of Rivaroxaban in Elderly Chinese Patients With Nonvalvular Atrial Fibrillation
Dan Zhang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2023)
Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
Xiao-qin Liu et al.
ACTA PHARMACOLOGICA SINICA (2022)
Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study
Feilong Zhang et al.
CLINICAL PHARMACOKINETICS (2022)
Rivaroxaban population pharmacokinetic and pharmacodynamic modeling in Iranian patients
Tayebeh Esmaeili et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2022)
A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation
Nan Zhao et al.
FRONTIERS IN PHARMACOLOGY (2022)
Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation
Jean Terrier et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease
Stefan Willmann et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2022)
Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation
Noppaket Singkham et al.
PHARMACEUTICS (2022)
Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions
Stefan Willmann et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)
Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation
Yan Wang et al.
FRONTIERS IN PHARMACOLOGY (2021)
Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS
Takanori Ikeda et al.
PLOS ONE (2021)
Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing
Emmanouela Kampouraki et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)
Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles
Eri Goto et al.
DRUG METABOLISM AND PHARMACOKINETICS (2020)
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
Christoph Male et al.
LANCET HAEMATOLOGY (2020)
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation
Guy Young et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism
Isabel Reinecke et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Liping Zhang et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)
Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation
Yi-Hsin Chan et al.
HEART RHYTHM (2020)
Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation
Hee Tae Yu et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis
Victoria Speed et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study
Jurij Zdovc et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation
Yi-Hsin Chan et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation
So-Ryoung Lee et al.
YONSEI MEDICAL JOURNAL (2019)
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome
Liping Zhang et al.
THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE (2019)
Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study
Pierre Amarenco et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2019)
An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1)
Shinya Suzuki et al.
DRUG METABOLISM AND PHARMACOKINETICS (2018)
The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation
Hsin-Fu Lee et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
Stefan Willmann et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study
Stefan Willmann et al.
THROMBOSIS JOURNAL (2018)
A Cross-Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies
Liping Zhang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
The impact of body weight on rivaroxaban pharmacokinetics
Sarah J. Barsam et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2017)
Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions
Tomas Kvasnicka et al.
CURRENT DRUG METABOLISM (2017)
Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement
Salmaan Kanji et al.
CLINICAL PHARMACOKINETICS (2015)
What do we learn from repeated population analyses?
Stephen B. Duffull et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Reporting a Population Pharmacokinetic-Pharmacodynamic Study: A Journal's Perspective
Kris M. Jamsen et al.
CLINICAL PHARMACOKINETICS (2014)
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2014)
Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
Toby Trujillo et al.
DRUGS (2014)
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Patients with Non-valvular Atrial Fibrillation: Results from ROCKET AF
I. G. Girgis et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects
Wolfgang Mueck et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
The J-ROCKET AF Study: A Matter of Ethnicity or a Matter of Weight?
Masatsugu Hori et al.
CIRCULATION JOURNAL (2013)
Confirmation of Model-based Dose Selection for a Japanese Phase III Study of Rivaroxaban in Non-valvular Atrial Fibrillation Patients
Masato Kaneko et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
Model-based Dose Selection for Phase III Rivaroxaban Study in Japanese Patients with Non-valvular Atrial Fibrillation
Takahiko Tanigawa et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
The effect of food on the absorption and pharmacokinetics of rivaroxaban
Jan Stampfuss et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes
Xu Steven Xu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation - The J-ROCKET AF Study
Masatsugu Hori et al.
CIRCULATION JOURNAL (2012)
Rivaroxaban Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
Xia Zhao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Population pharmacokinetics and pharmacodynamics of rivaroxaban - An oral, direct factor Xa inhibitor in patients undergoing major orthopaedic surgery
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2008)
Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
Lars C. Borris et al.
THROMBOSIS AND HAEMOSTASIS (2008)
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects
D Kubitza et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
分享论文
